Biochem/physiol Actions
Cinaciguat, also known as BAY 58-2667, is a novel activator of guanylate cyclase. It is used in the treatment of acute decompensated heart failure (ADHF). It has been reported that cinaciguat possesses cardiovascular effects.
Cinaciguat activates sGC (soluble guanylate cyclase) independently of NO. Cinaciguat binds to sGC′s NO-sensory H-NOX domain when it is heme-depleted. Also, the compound Cinaciguat protects sGC from oxidation-induced ubiquitin-triggered degradation.
Packaging
5, 25 mg in glass bottle
                             
                        
                            
                                
                                    This product has met the following criteria to qualify for the following awards: